Novo Nordisk (NVO) is lowering the price of its popula🅷r weight-loss drug Wegovy for some patients paying oꦆut of pocket. 

Wegovy will now be available for $499 per month at all dose levels through NovoCare Pharmacy, the drugmaker’s new direct-to-patient delivery offering, Novo Nordisk said Wednesday. The offer applies to patients without insurance or those with commercial insurance that doesn’t cover obesity medications. Patients could previously buy the drug without insurance for $650 per month, according to the company's website.

The move comes after a recent 澳洲幸运5官方开奖结果体彩网:Food and Dru🌼g Administration decision that the active ingredient in Wegovy and Novo Nordisk's other weight-loss treatment Ozempic was no longer considered to be in short supply. Last month, rival drugmaker Eli Lilly (LLY) also 澳洲幸运5官方开奖结果体彩网:dropped the price of its popular weight-loss drug Zepbound for self-paying patients on the heels of a 澳洲幸运5官方开奖结果体彩网:similar FDA ruling. 

Between them, Novo Nordisk and Eli Lilly dominate a weight-loss market that Goldman Sachs analysts reportedly said could 澳洲幸运5官方开奖结果体彩网:reach $130 billion by 2030.

Shares of Novo Nordisk rose close to 4% intraday Wednesday, but have lost about a quarter of their value over the past 12 months.  

CORRECTION—March 5, 2025: This article has been corrected to reflect Novo Nordisk made its announcement Wednesday.